Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001628280-25-020724
Filing Date
2025-04-29
Accepted
2025-04-29 16:35:07
Documents
18
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A carm-20241231.htm   iXBRL 10-K/A 430037
2 EX-3.1 exhibit31.htm EX-3.1 65968
3 EX-31.3 exhibit313.htm EX-31.3 4608
4 EX-31.4 exhibit314.htm EX-31.4 4608
  Complete submission text file 0001628280-25-020724.txt   1030677

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT carm-20241231.xsd EX-101.SCH 1905
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT carm-20241231_lab.xml EX-101.LAB 133549
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT carm-20241231_pre.xml EX-101.PRE 71690
20 EXTRACTED XBRL INSTANCE DOCUMENT carm-20241231_htm.xml XML 7714
Mailing Address 3675 MARKET STREET SUITE 401 PHILADELPHIA PA 19104
Business Address 3675 MARKET STREET SUITE 401 PHILADELPHIA PA 19104 2674916422
Carisma Therapeutics Inc. (Filer) CIK: 0001485003 (see all company filings)

EIN.: 262025616 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-36296 | Film No.: 25888376
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)